Developing inhibitors for cancer-related gene activity
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
This study is looking for new medicines that can help fight cancer by blocking certain proteins that help cancer grow, especially those linked to gene changes, and it's designed for people who are dealing with cancer caused by these mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11103190 on NIH RePORTER |
What this research studies
This research focuses on creating new drugs that inhibit specific proteins involved in cancer development, particularly those related to oncogenes, which are genes that can lead to cancer when mutated. The approach involves targeting epigenetic mechanisms that regulate gene expression, rather than directly targeting the oncogenes themselves. By screening for small molecules that can disrupt the activity of these proteins, the researchers aim to find effective treatments for cancers driven by these mutations. The study includes detailed biochemical assays and structural analysis to understand how these inhibitors work at a molecular level.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers driven by specific oncogene mutations, particularly those involving transcription factors.
Not a fit: Patients whose cancers are not driven by oncogene mutations or those with advanced-stage cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat various oncogene-driven cancers.
How similar studies have performed: Previous research has shown promise in targeting epigenetic regulators for cancer treatment, indicating that this approach could be viable.
Where this research is happening
Cambridge, United States
- Broad Institute, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Hahn, William C. — Broad Institute, INC.
- Study coordinator: Hahn, William C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.